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Although asthma is characterized as an inflammatory disease, recent reports highlight
the importance of pulmonary physiology outcome measures to the clinical assessment of
asthma control and risk of asthma exacerbation. Murine models of allergic inflammatory
airway disease have been widely used to gain mechanistic insight into the pathogenesis
of asthma; however, several aspects of murine models could benefit from improvement.
This review focuses on aligning lung mechanics measures made in mice with those made
in humans, with an eye toward improving the translational utility of these measures.
A brief description of techniques available to measure murine lung mechanics is provided
along with a methodological consideration of their utilization. How murine lung mechanics
outcome measures relate to pulmonary physiology measures conducted in humans
is discussed and we recommend that, like human studies, outcome measures be
standardized for murine models of asthma.
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ASTHMA CONTROL
Asthma is a chronic inflammatory disorder of the airways charac-
terized by paroxysmal or recurring symptoms that are associated
with variable airflow obstruction and bronchial hyperresponsive-
ness (Lougheed et al., 2012). Structural changes to the airways
often occur and this remodeling may be associated with persistent
disease and a progressive decline in lung function.
Given the heterogeneity and complex pathophysiology under-
lying asthma, disease progression should be carefully assessed
and closely monitored to achieve successful management. Goals
of asthma management per the National Asthma Education
Prevention Program (NAEPP) guidelines include minimization
of asthma symptoms, optimization of lung function, and pre-
vention of exacerbations (NAEPP, 2007). Simply put, the goal of
asthma treatment is to “control” the disease. The NAEPP and a
more recent guideline by the American Thoracic Society (ATS)
(Reddel et al., 2009) define asthma control as “the extent to
which the various manifestations of asthma have been reduced
or removed by treatment.” In other words, effective asthma treat-
ment should hinder the progression of the disease from mild to
moderate and moderate to severe and reduce the frequency and
Abbreviations: NAEPP, National Asthma Education Prevention Program; ATS,
American Thoracic Society; AHR, Airway hyperresponsiveness; FVC, Forced vital
capacity; FEV1, Forced expired volume in 1 second; FEF 25–75%, Forced expired
flow from 25–75% vital capacity; PEF, Peak expiratory flow; β1-AR, β1-adrenergic
receptor; β2-AR, β2-adrenergic receptor; BD, Bronchodilator; MCh, Methacholine;
PC20, Provocative concentration of bronchoconstrictor causing a 20% decline
in FEV1; PenH, Enhanced pause; RL, Lung resistance; FOT, Forced oscilla-
tion technique; Cdyn, Dynamic pulmonary compliance; V, Lung Volume; P,
Transpulmonary pressure; OVA, Ovalbumin; NIAID, National Institute of Allergy
and Infectious Diseases; APTI, airway pressure time index; PEEP, Positive end
expiratory pressure.
severity of asthma “attacks,” thereby reducing impairment and
future risk.
The definition of asthma has not changed much over the last
few decades; however, how asthma is assessed and how these
assessments correlate to the progression of the disease has recently
undergone modification. Recognizing the importance of “asthma
control” to quality of life, the ATS recently assembled a task force
to provide consensus recommendations to standardize the defi-
nition of, and assessment methods for, asthma control (Reddel
et al., 2009). In brief, whereas the term “asthma control” was
once defined by an examination of a patient’s recent clinical
state [including symptoms, reliever use, lung function, and air-
way hyperresponsiveness (AHR)], it now includes an assessment
of future risk. Similar to the NAEPP guidelines, the ATS guidelines
recommend that both clinical state and future risk be assessed to
characterize asthma control in both clinical practice and clinical
trials.
CLINICAL ASSESSMENT OF ASTHMA CONTROL
Current clinical approaches characterize asthma based on four
defining domains; symptoms, airway inflammation, airway
obstruction, and airway hyperresponsiveness. How are these
domains assessed and how do these assessments reflect asthma
control? Furthermore, how do these outcome measures com-
pare to those available in murine models of allergic inflammatory
airway disease?
DOMAIN 1: SYMPTOMS
Symptoms, including cough, wheeze, chest tightness, and dysp-
nea, can be measured using a variety of symptom diaries and
questionnaires (Reddel et al., 2009). Items such as symptom-free
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days and reliever use are recorded and quality of life is assessed
using questionnaires (Juniper et al., 1992; O’Byrne et al., 2005).
The use of symptoms as indicators of underlying physiologic and
immune status has been exploited through asthma action plans,
which provide patients with the ability to assess and exert some
level of control over symptom progression and reduce the need
for medical resource intervention (Gupta et al., 2012; Lougheed
et al., 2012). For obvious reasons assessment of symptoms is dif-
ficult in murine models, which tend to be strong on quantitative
measures of immune, physiologic, and histologic status.
DOMAIN 2: INFLAMMATION
Inflammation can be measured directly through bronchoscopy
and biopsy. However, these procedures are invasive, time consum-
ing, costly, and require expertise. Thus, inflammatory biomarkers
of asthma hold great allure, and have been keenly pursued. To
date, biomarkers such as exhaled nitric oxide, induced sputum
and serum eosinophils have proven useful in identifying asthmat-
ics having a predominant eosinophilic inflammatory phenotype
(Green et al., 2002; van Veen et al., 2008, 2009). Similarly, serum
periostin appears to be a promising marker of Th2 inflamma-
tion in asthmatics (Arron et al., 2011). However, none of the
current biomarkers of airways inflammation have proved clini-
cally meaningful with respect to asthma control (Holgate, 2012).
Thus, the search continues for a non-invasive biomarker of air-
way inflammation that can reliably and reproducibly characterize
asthma control. Genetic and experimental murine models of
asthma are strong on the potential to assess inflammatory sta-
tus through BAL, blood, histology, and molecular mechanisms,
although it has been suggested that such models may not translate
as well as one would hope with respect to human health (Holgate
and Polosa, 2008). Perhaps a key factor that was missing for
the exploitation of murine models was a more precise classifica-
tion of human asthma based on pathophysiological mechanisms.
Improved characterization of human asthma into recently defined
“endotypes” (Lötvall et al., 2011; Agache et al., 2012) coupled
with murine models that better target human signs and symp-
toms have the potential to enhance further the translation/impact
of murine models. Additionally, the power of the murine models
is vested within the controlled genetic background of laboratory
mice, the restricted and consistent animal care environment and
an ability to induce single gene mutations to provide a genotype-
phenotype assessment. This magnitude of control, although far
from fully transparent with respect to genotype-phenotype asso-
ciations, is far more precise than the continuum of environmental
exposures experienced by human asthmatics with highly variable
genetic backgrounds.
DOMAIN 3: LUNG FUNCTION (AIRWAY OBSTRUCTION
AND BRONCHODILATOR REVERSIBILITY)
Lung function in asthma is assessed clinically using spirometric
methods that rely on the forced vital capacity (FVC) and derived
measures such as forced expired volume in 1 second (FEV1),
forced expired flow from 25–75% vital capacity (FEF 25–75%), or
peak expiratory flow (PEF) (Reddel et al., 2009; Lougheed et al.,
2012). Although these measures are typically made in the labora-
tory, ambulatory PEF is also reliably self-measured in the patient.
Despite the convenience of ambulatory PEF measurements, FEV1
and the FEV1/FVC ratio are currently the customary diagnos-
tic spirometric measures used to characterize airflow limitation
and bronchodilator (BD) responsiveness in asthmatics (Reddel
et al., 2009; Lougheed et al., 2012). Although it is tempting to
link spirometric FEV1 and FEV1/FVC measurements to airway
or lung resistance (RL), this is a complex relationship and “test of
forced expiration and the direct measurement of airway resistance
should not be regarded as invariably interchangeable” (Pride,
1971). Indeed, thorough and still valid historical perspectives of
the factors affecting FEV1 and resistance outline the dependence
of FEV1 on lung elastic recoil as well as intrapulmonary air-
way resistance (Pride, 1971). Nevertheless, spirometry and the
FEV1 and FVC measurements are components of the diagnostic
mainstay from which clinicians gain insight into the degree of air-
way narrowing, an indicator of disease progression and severity.
Airway narrowing, or the average airway lumen diameter, reflects
the complex interactions among physiologic and pathophysi-
ologic events including airway inflammation, remodeling, and
smooth muscle shortening, the latter two being of greater deter-
minative importance. Airway smooth muscle shortening, which
reduces airway diameter (Cabezas et al., 1971), is determined by
the bronchoconstrictor reactivity and/or sensitivity (“responsive-
ness”) of the muscle itself and the structural load against which
the muscle must pull (McParland et al., 2003). Airway remodel-
ing is a broad term that includes structural changes to the airway
mucosa (i.e., goblet cell hyperplasia and mucus hypersecretion)
and submucosa (i.e., reticular basement membrane thickening)
along with thickening of the airway wall (i.e., ASM hypertro-
phy/hyperplasia) (McParland et al., 2003; Broide, 2008; Evans
et al., 2009; GINA, 2011; Shifren et al., 2012). This structural
remodeling results in encroachment of the airway lumen, the
extent of which is reflected by the magnitude of “irreversible”
or “fixed” airway obstruction (McParland et al., 2003; GINA,
2011; Shifren et al., 2012) A clue as to the relative contributions
of ASM shortening and airway remodeling to airway narrowing
can be derived from considering pre- and post-BD FEV1 values.
Whereas a BD, usually a β2-adrenergic receptor (β2-AR) ago-
nist, has no immediate effect on airway remodeling, it will relax
airway smooth muscle thereby reducing airway narrowing. This
BD-induced demonstration of rapidly reversible airflow obstruc-
tion is one of the hallmark features of asthma (GINA, 2011)
and sheds light on the relative magnitude of reversible (ASM
shortening) vs. fixed (remodeling) airway obstruction present in
asthmatics (Bumbacea et al., 2004). However, interpretation of
β-agonist-induced reversibility maneuvers may be confounded
by β2-AR dysfunction which is prevalent in severe asthmatics
(Newnham et al., 1994, 1995; Grove and Lipworth, 1995; Taylor,
2009) or by remodeling-induced changes to airway geometry that
amplify the airway narrowing effect of bronchoconstrictor stimuli
(Lambert et al., 1993; McParland et al., 2003).
Airway narrowing increases the resistance to airflow through
the airways thereby “limiting” or “obstructing” airflow, leading to
a fall in spirometric indices of lung function, as well as dynamic
lung hyperinflation and loss of inspiratory capacity (Lougheed
et al., 2006). This in turn increases the work of breathing and leads
to an array of complex and incompletely understood mechanical
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and sensory factors that manifest as dyspnea, chest tightness or
other symptoms (O’Donnell et al., 2009). Thus, the challenge
of translating human asthma and its diagnostic assessment to
murine models is significant (Holgate, 2012). In mice, voluntary
maneuvers are impossible. Some investigators have used negative
pressure expiration inmice to simulate a forced expired maneuver
(Lai and Chou, 2000; Gebel et al., 2010; Vanoirbeek et al., 2010);
however, the outcome measures derived from this technique have
not been thoroughly validated. Despite this limitation, quantita-
tive and reliable measures of RL and elastance can be produced
in mice as well as changes in lung volume (Vinegar et al., 1979;
Martin et al., 1988).
DOMAIN 4: AIRWAY HYPERRESPONSIVENESS
AHR is a broad term that reflects the degree of airway narrow-
ing in response to a given concentration of bronchoconstrictor.
Thus, by definition, AHR is a measure of the complex interactions
between ASM shortening and airway remodeling. Although AHR
is detected using the FVC technique, which provides standard
measures of lung function, critical insight is reflected by the sensi-
tivity and reactivity of the asthmatic’s airway to the bronchocon-
strictor. AHR, or bronchial hyperresponsiveness, is assessed by
measuring changes in function (i.e., the drop in the FEV1)
from baseline with increasing inhaled concentrations of “direct”
smooth muscle contractile agonists (e.g., methacholine, MCh) or
“indirect” bronchoconstrictor stimuli (e.g., mannitol, an osmotic
stimulus, or cold air) (Brannan and Lougheed, 2012; Tepper et al.,
2012). From the constrictor-induced changes in FEV1 one can
measure or calculate (via log-linear interpolation) the provoca-
tive concentration of bronchoconstrictor that has caused, or will
cause, a particular magnitude of airway narrowing, typically a
20% decline in FEV1 (PC20). AHR is a highly-standardized,
objective and reproducible outcome measure (Reddel et al., 2009;
Tepper et al., 2012).
ALTERNATIVE LUNG MECHANICS TESTS
By modifying commonly used measurement techniques, indices
of lung mechanics can be further assessed. For example, hyper-
inflation, inferred from changes in lung volumes measured
by spirometry, is indicative of gas trapping secondary to air-
way obstruction and may occur in asthmatics (for example see
Lougheed et al., 2006). Additionally, combining whole body
plethysmography with bronchial challenge testing in humans
can provide, usually in a research setting, a measure of airway
resistance (Tepper et al., 2012). An alternative technique to the
resistance measurements obtained through body plethysmogra-
phy is the use of the forced oscillation technique (FOT) (Dubois
et al., 1956). In this technique a specialized pressure generating
device is computer-programmed to produce multiple simultane-
ous variations in airflow frequency (input) and sensitive pressure
transducers capture the respiratory system pressure response
(output) to this perturbation. A comparison of the Fourier trans-
formed input and output data with respect to frequency gives
the respiratory system impedance, from which airway resistance
and elastance are calculated (Bates et al., 2011). Although the
FOT is not routinely used clinically, it offers one major advan-
tage in that it can be easily used in patient populations that
are unable to perform the forced expired maneuvers (like the
elderly or very young) (Bates et al., 2011; Tepper et al., 2012).
Interestingly, the FOT is the same as that used by some investi-
gators to assess murine respiratory system mechanics (Schuessler
and Bates, 1995; Irvin and Bates, 2003).
ASTHMA CONTROL OUTCOME MEASURES
As mentioned previously, asthma control is characterized by a
patient’s recent clinical state and future risk of adverse events.
The recent clinical state is assessed through characterization of
symptoms, frequency of reliever use and lung mechanics data.
Specifically, lung function and AHR measurements are made
using pulmonary function tests such as pre- and post-BD FEV1,
PEF, and AHR. Future risk, the second component of asthma con-
trol, is defined as the probability of adverse outcomes such as
worsening of the clinical state, increased exacerbations and accel-
erated decline in lung function. Since exacerbations, are defined
as “events characterized by a change from the patient’s previous
status,” they implicitly include the same measurements as those
described above for clinical state. However, the frequency and
intensity of exacerbations holds additional information for the
clinician. Currently, human lung mechanics measurements (lung
function and AHR) are themost important measures for assessing
and predicting the course of asthma.
CLINICAL RELEVANCE
A wide variety of outcome measures, including symptoms,
inflammation, and lung mechanics, are available to clinicians to
characterize the current state and progression of asthma. Busse
et al., recently suggested that AHR should be the “therapeutic or
interventional target” (Busse, 2010) and evidence suggests that
the use of MCh-induced AHR as a guide to treatment improves
asthma control (Sont et al., 1999). AHR is also predictive of the
effectiveness of inhaled corticosteroid therapy to mitigate lung
function changes in asthmatics (Brutsche et al., 2006). Taken
together, AHR is an indirect, but consequential marker of asthma
control. In fact, those diagnosed with asymptomatic AHR often
go on to develop asthma (Brutsche et al., 2006). Alternatively,
lung function, as measured by spirometry (FEV1) has a high
predictive value of asthma control including asthma exacerba-
tions and asthma-related death. Indeed, some clinicians opine
that AHR, although informative, is only a secondary measure
of importance relative to pre- and post-BD FEV1 (Tepper et al.,
2012). The overarching conclusion drawn by the ATS task force is
that the best measurements currently available to accurately assess
asthma control in clinical practice or clinical trials are both lung
function and AHR (Reddel et al., 2009).
Although somewhat counterintuitive, given that inflamma-
tion is a foundational component of the definition of asthma
(Lougheed et al., 2012), inflammatory status is not listed in the
guidelines as a primary indicator of asthma control (Reddel et al.,
2009). Although airways inflammation likely contributes to the
development of symptoms and airflow obstruction, it does not
closely associate with AHR (Rosi et al., 1999; Haldar et al., 2008;
Busse, 2010). Perhaps consequently, inflammatory biomarkers
have not been validated as tools for assessing asthma control
as they too are not consistently associated with lung mechanics
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outcome measures. In addition to lung mechanics and inflam-
mation outcome measures, clinicians have available a battery of
methods to assess symptoms. Symptom perception is a significant
factor in lung diseases; however, evidence suggests that symp-
toms are not closely associated with AHR or, in some cases,
lung function and are therefore, dissociated from asthma con-
trol (Lougheed, 2007). For example, Jenkins et al, showed that
LABA therapy that results in improved symptoms does not corre-
spondingly improve airway obstruction as measured by pre-BD
FEV1 (Jenkins et al., 2005). The importance of lung function
and AHRmeasurements to guide clinicians in their assessment of
asthma control is well-supported and, by analogy, emphasizes the
importance of making lung function/lung mechanics measures in
mice that provide data with comparable physiologic meaning and
insight into pathophysiologic mechanisms.
ASSESSING OUTCOME MEASURES IN MURINE MODELS
OF ASTHMA
SYMPTOMS AND INFLAMMATION
The murine correlate to asthmatic signs and symptoms is lacking.
Symptoms cannot be communicated by animals. Furthermore,
signs of the disease are not reliably displayed by prey species such
as mice, nor interpreted by investigators. Mice do not appear
to be capable of cough (Pack et al., 1984). The challenges of
assessing wheeze, chest tightness, dyspnea, or other stress-related
symptoms in mice are high. However, stress has been shown to
influence the outcome of murine models of asthma (Quarcoo
et al., 2009; Vig et al., 2010) and tools are available to assess or
account for animal behavior (Hurst and West, 2010). Although
utilization of these tools to assess murine signs of disease is
beyond the scope of the present review, they may provide an,
as yet, untapped opportunity to address mechanisms of dyspnea
(O’Donnell et al., 2009). However, evaluating signs of asthma in
mice is not currently practical.
On the other hand, mouse models permit much greater pro-
curement of immunological and histological data than human
methods (Lin et al., 2012), although care must be taken
to not over-interpret immunological outcomes that are not
well-supported by lung mechanics outcomes. Mullane recently
reviewed studies in which immunological mechanisms underly-
ing the pathophysiology of asthma were elucidated using murine
models (Mullane, 2011). The relevance of these pathways to
asthma pathogenesis was evaluated through mouse phenotyping
that included measurement of AHR and indices of inflamma-
tion. Mullane’s analysis illustrated that approximately only one
quarter of the immunologic targets identified in murine stud-
ies showed positive therapeutic effects when manipulated in
asthmatics. Although this appears to be a low yield on the
potential of immunological targets translated to human clinical
trials, our reexamination of the murine models in which AHR
was shown to be diminished in response to intervention at a
particular immunologic target suggests a more promising out-
come (Table 1). Reexamination of the data is consistent with the
notion that much of the translational value of murine immuno-
logic mechanistic studies may rely on the concomitant rigor of
AHR measurements. For example, immunologic pathways that
produced positive or negative results when targeted clinically
were associated with murine studies where AHR measurements
were made more (i.e., invasive measures using appropriate dose
response protocols) or less (i.e., unmeasured or measured using
PenH or invasively with no dose response) stringently, respec-
tively. The low rate of translational success frommurinemodels to
human asthma is undoubtedly influenced by several factors other
than the stringency of AHR measurements including species
differences, timing of intervention in relation to disease pro-
gression, genetic and environmental heterogeneity of the asth-
matic (vs. the murine) population and the suitability of acute
animal modeling of a chronic disease. However, a prevailing
hypothesis appears to be that mechanistic information derived
from mouse models of asthma will be more relevant clinically
(more translatable) if AHR measurements are more rigorous
(see next section). Interestingly, this notion echoes the conclu-
sion reached by an NIH expert group that reviewed pulmonary
function techniques for asthma with respect to the benefit of
standardized and rigorous measures of lung function in human
asthma (Tepper et al., 2012). Similar standardization for lung
mechanics measurements in murine models of asthma would be
prudent.
MURINE LUNG MECHANICS MEASUREMENT TECHNIQUES
Several excellent reviews of the experimental validation, practical
applications, feasibility, and limitations of experimental tech-
niques for measuring lung mechanics in mice are available in the
literature (Irvin and Bates, 2003; Glaab et al., 2007). Here, we
provide a brief summary of these techniques and a discussion of
how they can be optimized and possibly standardized for use in
murine models of lung disease.
In a remarkable foreshadowing of the explosion of murine
models of asthma, Martin et al. (1988) alluded to the attractive-
ness of murine models in immunology and genetics coupled with
an acute need for robust measures of pulmonary mechanics and
airway responsiveness. They successfully scaled-down standard
plethysmographic techniques formeasuringRL (and its reciprocal
conductance) and dynamic pulmonary compliance (Cdyn) (and
its reciprocal elastance) in larger animal models (Mead, 1961)
to accurately assess these variables in the mouse during intra-
venous challenge with a range of bronchoconstrictor and BD
agents. Indeed, this study represents the foundation for modern
approaches to the measurement of murine lung function (Ewart
et al., 1995; Volgyesi et al., 2000; Irvin and Bates, 2003; Glaab et al.,
2007). The classic method of measuring pulmonary mechanics
in mice requires the measurement of transpulmonary pressure,
airflow and tidal volume from which the lung function parame-
ters total RL (the sum of frictional airflow and pulmonary tissue
resistances) and Cdyn can be calculated [by fitting them to an
equation of motion (Amdur and Mead, 1958; Mead, 1961; Irvin
and Bates, 2003)].
P = V × 1/C + RL × Flow
(P, transpulmonary pressure; V, lung volume relative to func-
tional residual capacity; C, compliance; RL, total lung resistance;
Flow, air flow through the airways).
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Table 1 | The impact of AHR measurement methodology on translation of immunological targets is shown below.
Immune target Murine AHR Effect of clinical
targeting
References Method of AHR measurement Bronchoconstrictor
IL-1 ↓ No Wang et al., 2006 PenH, no validating measure aerosolized MCh,
0–50mg/mL
IL-10 ↑ No van Scott et al., 2000 Esophageal Ptp, flow pneumotach i.v. MCh up to 1000ug/kg
IL-10 ↓ No Stämpfli et al., 1999 End-inflation occlusion i.v. MCh up to 1000ug/kg
IL-12 ↓ No Gavett et al., 1995 APTI i.v. Ach, single dose at
25 ug/kg
IL-12 ↓ No Kips et al., 1996;
Brusselle et al., 1997
Needle Ptp, flow pneumotach i.v. carbachol 20 to
400ug/kg
IL-13 ↓ No Karras et al., 2007 PenH dose response, baseline
included, single dose FOT
MCh aerosol,
0–100mg/mL; i.v. MCh
single point
IL-13 ↓ No Munitz et al., 2008 FOT; 2 cmH2O PEEP aerosolized MCh,
25–100mg/mL
IL-13 ↓ No Grünig et al., 1998 PC200RL, baseline not provided;
APTI and flow plethysmography
i.v. Ach, dose not given
IL-13 ↓ No Wills-Karp et al., 1998 APTI i.v. Ach, single dose at
50 ug/kg
VLA-4, original ↓ No Koo et al., 2003 Eos in lung by BALF and histology,
no AHR measure
N/A
CD11a N/A No Rabb et al., 1994 Not measured N/A
LTB4 N/A No Walsh and August, 2010 Not measured N/A
LTB4 N/A No Waseda et al., 2011 Not measured N/A
IFN N/A No Iwamoto et al., 1993 Not measured N/A
IL-4R ↓ Positive Rankin et al., 1996 Flow-plethysmography, PC100RL MCh aerosol, begin dose
0.001mg/mL
IL-4R ↓ Positive Corry et al., 1996 APTI and Flow-plethysmography i.v. MCh, 5 pt dose
response
IL-3/5 /GMCSF ↓ Positive Allakhverdi et al., 2002 Flow-plethysmography, EC200LTD4 i.t. LTD4; 50 to 1000ng
IL-3/5 /GMCSF ↓ Positive Allakhverdi et al., 2006 Flow-plethysmography, EC200LTD4 i.t. LTD4; 50 to 1000ng
IL-2 ↓ Positive Doganci et al., 2008 Flow-plethysmography; ED200RL i.v. MCh 33 to 3300ug/kg
Selectin ↓ Positive De Sanctis et al., 1997 Flow-plethysmography; ED200RL i.v. MCh 33 to 1000ug/kg
IL-5 variable Positive Garlisi et al., 1999 AHR not measured N/A
IL-5 variable Positive Mauser et al., 1993 ED100RL and ED40Cdyn Substance P
Note that the immunological mediators identified in studies where AHR was not measured produced no significant effect when targeted clinically. i.v., intravenous;
i.t., intratracheal; PC100RL, provocative concentration causing a 100% change in lung resistance; LTD4, leukotriene D4; MCh, methacholine; N/A, not applicable.
Thus, transpulmonary pressure, calculated as the difference
between directly measured mouth and intrapleural pressures, has
an elastic component (V × 1/C) and a flow-resistive compo-
nent (RL× Flow) and these can be evaluated separately. When
gas flow ceases (at end-inspiration and end-expiration) the
flow-resistive component of the equation drops out and com-
pliance can be calculated based on P and V. To calculate RL,
transpulmonary pressure and Flow are measured at points of
equal volume during the respiratory cycle (where elastic pres-
sures will be approximately equal) so that the transpulmonary
pressure difference between these two points reflects total RL
(Amdur and Mead, 1958). As the equation suggests both air-
flow and transpulmonary pressure are required to calculate
resistance. Given that mice have extremely small tidal volumes,
airflow is difficult to measure unless appropriately sized pneu-
motachographs are constructed (Mortola and Noworaj, 1983);
thus, the flow signal is often measured by electronic differ-
entiation of the volume signal which is generated using the
plethysmograph technique. Intrapleural pressure can be mea-
sured directly or indirectly by connecting a fluid-filled intrapleu-
ral catheter or an esophageal balloon, respectively, to a pressure
transducer.
Current methods that assess murine pulmonary function
can be categorized broadly into invasive (Figures 1A–D) and
non-invasive (Figure 2) techniques. Invasive techniques directly
measure respiratory system (including chest-wall) or pulmonary
(lung only) mechanics and typically rely on tracheal cannula-
tion or orotracheal intubation to measure airflow and pressure
across the respiratory system or across the lung (transpulmonary
pressure). Based on physiological principles these methods pro-
vide reproducible, consistent, andmeaningful data with respect to
RL and elastance, which are sufficiently sensitive to reveal subtle
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FIGURE 1 | Examples of routine methods of Respiratory mechanics
Measurements for AHR: each panel illustrates animal instrumentation,
airway measurement (s) and presence of mechanical or spontaneous
ventilation. (A) Airway Pressure Time Index: APTI measures the tracheal
pressure response to MCh in a mouse to calculate an aggregate change in
respiratory system impedance (Levitt and Mitzner, 1988). (B) Flow
Plethysmography: Flow and tracheal pressure (Ptr) signals derived from a
flow-plethysmograph and tracheal cannula are used to calculate Rrs or RL
depending on whether transrespiratory or transpulmonary pressure is
measured (Amdur and Mead, 1958; Waldron and Fisher, 1988). (C)
End-Inflation Occlusion: This technique relies on a purpose built ventilator
to deliver and hold known inflation volumes and measure the resultant
pressure peak and plateau pressures to calculate Rrs and Crs (Ewart et al.,
1995; Volgyesi et al., 2000). Ventilators may be lab constructed or use a
commercial product (Volgeysi ventilator). (D) Forced Oscillation
Technique: The FOT method relies on a purpose built ventilator requiring
sophisticated software for the control of volume perturbations and analysis
of generated pressure, volume and flow signals. In brief, ventilator housed
pistons generate a complex frequency perturbation in the volume signal
administered to mice. The lung response is measured as pressure from
which lung impedance and other variables are calculated. Current use
applications in the literature appear to be restricted to a commercially built
ventilator (Scireq®flexivent).
changes in lung mechanics induced by allergen-exposure mod-
els (Irvin and Bates, 2003; Glaab et al., 2007). Thus, invasive
techniques are valuable tools for assessing AHR in murine models
of asthma.
The primary drawback to the invasive methods, with the
exception of the technically challenging orotracheal intuba-
tion method (Polikepahad et al., 2010; De Vleeschauwer et al.,
2011), is the inability to make repeated measurements. A second
disadvantage of measuring lung mechanics invasively is the need
for anesthesia. Anesthesia will alter autonomic nervous system
tone which may impact bronchoconstriction and/or mucin secre-
tion (Dripps and Severinghaus, 1955; GINA, 2011). Whereas
it is possible to make invasive lung mechanics measurements
in conscious animals (Amdur and Mead, 1958), minor recov-
ery surgery is required to place a fluid-filled catheter in the
intrapleural space and significant restraint is required during
measurements. Moreover, the challenge of making conscious
lung mechanics measurements reflects what Amdur and Mead
(Amdur and Mead, 1958) described as “the act of breathing”
and the presence of movement and other artifacts that may yield
a less sensitive measurement. For this very reason, non-invasive
techniques, such as head-out body plethysmography (Figure 2)
(Vijayaraghavan et al., 1994), that indirectly assess murine pul-
monary function generate results that are less accurate and less
reproducible than invasive measures (Glaab et al., 2007). Should
non-invasive techniques evolve, it is important that they be val-
idated against standard measures of lung and respiratory system
mechanics prior to their widespread use (Mead, 1961; Irvin and
Bates, 2003; Mitzner and Tankersley, 2003). The lack of such an
approach leads to the adoption of techniques, which although
attractive in application, may be neither valid nor appropriate
experimentally (Irvin and Bates, 2003; Glaab et al., 2007). For
example, the non-invasive technique for specific airway resis-
tance originally developed by Pennock et al. (1979) relied on
a well-recognized double chamber plethysmograph apparatus,
in which signals from the thoracic (body) and head chamber
allow one to obtain flow and pressure signals from which bron-
choconstriction was estimated and this method was validated
against traditional “gold standard” mechanics measurements.
Subsequently, the Pennock method was modified and marketed
as the PenH, or enhanced pause, method that claimed to pro-
vide an indirect measure of respiratory mechanics by placing a
conscious unrestrained animal in a whole-body plethysmograph
and simply measuring changes in chamber pressure (Hamelmann
et al., 1997). The whole body plethysmograph approach, where
the subject is placed within a sealed chamber, originated as a
method to assess ventilation in conscious infants (Drorbaugh and
Fenn, 1955) and has been validated for measurements of tidal
volume and respiratory frequency based on variations in the pres-
sure of the closed system according to the barometric method
(Drorbaugh and Fenn, 1955). This method has been modified to
accommodate other species including mice (Walker et al., 1997;
Mortola and Frappell, 1998), for which several theoretical con-
siderations have been elucidated for tidal volume measurement.
PenH was not part of the above-mentioned developments of the
barometric method tomeasure tidal volume and current evidence
suggests that calculating PenH, is not a theoretically or biologi-
cally accurate measure of lung or respiratory system mechanics
or of AHR (Drazen et al., 1999; Hantos and Brusasco, 2002; Bates
and Irvin, 2003; Kips et al., 2003; Mitzner and Tankersley, 2003;
Bates et al., 2004). Studies that correlate PenH with inflammatory
indicators or other variables are, unfortunately, insufficient proof
that PenH measures respiratory mechanics. Changes in PenH
do however indicate that alterations in the pattern of breathing
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FIGURE 2 | Non-invasive method to measure respiratory mechanics.
Mid-Expiratory Flow: Flow is measured at 50% of the expired
volume (EF50) from animals placed in a head-out plethysmograph.
A pneumotach placed in the chamber, face mask (in humans) or
tracheal cannula can be used to measure flow and volume
(Vijayaraghavan et al., 1994; Glaab et al., 2001). This method provides
an indirect assessment of resistance since the reduction in flow
reflects any source of airway narrowing from pulmonary airways to
changes in laryngeal adduction or even post inspiratory activation of the
diaphragm.
occur for conditions in which airway inflammation and possi-
bly airway narrowing are present. This is not surprising given the
rich array of airway afferents that are activated by inflammatory
mediators (Fisher and O’Donnell, 2009; Fisher, 2011). Further,
pattern of breathing changes can involve significant laryngeal
resistance and abnormal upper airway laryngeal function can
mimic asthma (Christopher et al., 1983; Morris and Christopher,
2012). An example of an “enhanced pause” that is not due to
AHR or tracheobronchial airway narrowing is seen in newborn
infants (Fisher et al., 1982; Mortola et al., 1982) where laryn-
geal adduction or closure, used to elevate lung volumes and clear
pulmonary fetal liquid, leads to “enhanced pauses” that would
provide erroneous conclusions about AHR based on PenH.
An appreciation for how the classic parameters (RL and Cdyn)
relate to lung structure and function in mice is not completely
understood (Mitzner, 2007); however, in an idealized lung model
airways resistance is directly linked to airway luminal diameter
and airway closure can be quantified by measuring lung elastance
(reciprocal of compliance) (Mitzner, 2007). Numerous invasive
methods for determining RL and Cdyn have been described
above, each of which involves anesthetized and tracheally instru-
mented animals. Unless longitudinal measures of lung mechanics
are the focus of a study, we recommend that these invasive tech-
niques be the standard measure for assessment of murine lung
mechanics. One such method that has gained recent attention in
murine models of lung disease is the FOT which examines the
frequency-domain of lung mechanics (Figure 1D). Although the
FOT is not new (Dubois et al., 1956; Finucane et al., 1975), its
application to murine models is relatively recent (Schuessler and
Bates, 1995). The mathematical modeling underlying the FOT
is complex, but has been well-described by others (Hildebrandt,
1970; Hantos et al., 1987; Schuessler and Bates, 1995; Bates et al.,
2011) so will not be discussed here.
UTILITY OF LUNG MECHANICS TECHNIQUES
Two divergent opinions exist with respect to the usefulness of clas-
sic vs. the FOT for measuring lung mechanics in mice (Bates,
2007; Mitzner, 2007). One school of thought is that the tra-
ditional measures, resistance and compliance, derived from the
classic equation of motion (Mead, 1961) provide robust and
reliable data to quantify AHR, baseline pulmonary mechanics
and the impact of antigen-sensitization and challenge on them
(Mitzner, 2007). Indeed, even airway pressure time index (APTI)
(Figure 1A), a reflection of an aggregate change in respiratory
system impedance, is sufficiently sensitive to reveal the effect of
allergen-treatment on AHR (Walker et al., 2003). The other opin-
ion is that additional mechanistic insight into airway structural
changes can be generated by using complex mathematical model-
ing to examine how lung mechanics are influenced by frequency
(Bates, 2007; Lundblad, 2012). Extension of this viewpoint claims
that the FOT can provide (for both human and animal mod-
els) important physiological interpretations of disease progres-
sion and/or resolution associated with novel treatment strategies
(Wagers et al., 2004, 2007; Lundblad et al., 2007; Schweitzer et al.,
2010; Bates et al., 2011). Neither viewpoint is incorrect; as long
as study designs embrace quantitative (and validated) measure-
ments of lung mechanics as an outcome measure for murine
models of inflammatory lung disease, then themethods employed
largely reflect the goals of the investigator.
MURINE LUNGMECHANICS OUTCOME MEASURES
BASELINE RESISTANCE
The pre-BD FEV1 in humans reflects airway obstruction sec-
ondary to airway narrowing. Themouse correlate for determining
airway narrowing is baseline airway resistance. In an idealized
model, airway resistance mathematically reflects the luminal
diameter of the airways (Mitzner, 2007). Murine baseline air-
way resistance is sufficiently sensitive to allergen treatment that
changes can be detected using an acute ovalbumin (OVA) sen-
sitization and challenge model. As shown in Figure 3A, acute
OVA treatment increases baseline resistance relative to naïve con-
trols for at least two strains of mouse (C57BL/6J and BALB/C).
Comparison of the pre- and post-BD FEV1 in humans indicates
the reversibility of airflow obstruction, which reflects the level
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FIGURE 3 | Changes in baseline resistance are measureable in mice.
Baseline resistance was measured using the forced oscillation technique in
anesthetized, paralyzed, tracheotomized mice 24h after the last OVA
challenge (Lin et al., 2012). Duplicate measures of baseline resistance were
made in all mice. Animal experiments used to acquire these data were
approved by the Duke IACUC. (A) and (B) BALB/C mice were sensitized by
i.p. injection with 10 ug OVA adsorbed to 2.5mg alum on days 0 and 14 and
challenged by aerosol exposure with 1% OVA for 1 h on days 21, 22, and 23
(Walker et al., 2003). The effect of 60 ug/kg i.v. albuterol on baseline
resistance was assessed 1min after it was administered. (B) C57BL/6J
mice were sensitized by i.p. injection with 10 ug OVA adsorbed to 2mg
alum on days 1 and 6 and challenged by intranasal insufflation 25μL OVA
(0.2% w/v in saline) containing 2.5 nM of short scrambled peptide.
∗p < 0.05 from naïve (A) or pre-albuterol (B) as assessed by student’s
t-test.
of airway remodeling. Assessing the reversibility of airway tone
can also be accomplished in mice by administration of a β2-
AR agonist after initial baseline resistance has been measured.
Figure 3B shows a statistically significant decline in baseline resis-
tance immediately following i.v. delivery of 60 ug/kg albuterol in
BALB/C mice. Despite receptor expression data suggesting that
mice may mediate bronchorelaxation via β1-AR, it was recently
shown that the bronchoprotective effect of intravenous (30 ug/kg)
albuterol observed in wild type FVB/N mice is absent in β2-
AR−/− mutants (Lin et al., 2012). These data provide proof of
concept that BD reversibility can be measured in mice. As in
humans, measures of baseline resistance and BD reversibility may
provide insight into the mechanisms underlying airway narrow-
ing in mice, although correlation of these changes to airway
remodeling or airway smooth muscle shortening has yet to be
investigated. Additionally, airway remodeling studies necessitate
the use of a chronic murine model of asthma, the characteris-
tics and merits of which are reviewed in this issue by Kumar and
Foster (Kumar and Foster, 2012).
AIRWAY HYPERRESPONSIVENESS
AHR is a term that describes airway narrowing in response to a
bronchoconstrictor challenge. The ASM shortening component
of AHR consists of two main parts; increased sensitivity and
increased reactivity. Increased reactivity refers to excessive airway
narrowing in response to a contractile stimulus. Increased sen-
sitivity describes airway narrowing that occurs in response to a
smaller dose of bronchoconstrictor. To assess AHR in humans,
FEV1 is measured after each exposure to increasing doses of
constrictor. Similarly, increasing doses of MCh or other bron-
choconstrictor are used in mice; however, airway or total RL is
measured instead of FEV1. Irrespective of differences in mea-
surement techniques, lung mechanics measures are based on
physiologic principles that apply across species suggesting that the
pathophysiologic relevance of AHR measures in mice is translat-
able to humans, despite the inability to quantitatively compare
the two. Thorough assessment of AHR requires examination
of the response to several concentrations of bronchoconstric-
tor. To generate a typical dose response curve in mice, resistance
measurements are taken at baseline and immediately after expo-
sure to increasing doses of MCh. Airway resistance is plotted
on the ordinate and the dose or concentration of constrictor
on the abscissa. A leftward shift in the curve indicates increased
sensitivity, whereas an increased slope of the curve represents
increased reactivity. To calculate the slope, or reactivity, of the
response to bronchoconstrictor one can apply non-linear regres-
sion analysis and fit the data to an exponential growth function
(y = aekx). Alternatively, the resistance data may be natural
logarithm-transformed followed by linear regression analysis to
provide a straight line, the slope of which is an indication of reac-
tivity (Evans et al., 2003; Thanawala et al., 2013). It is thought
that the increased reactivity component of AHR is more clini-
cally relevant (Busse, 2010). Thus, an altered slope of the dose
response curve in mice is the outcome that is likely more translat-
able to human asthma. Unfortunately, despite the acceptance of
the notion that airway remodeling contributes at least in part to
excessive airway narrowing, and thus, AHR, a definitive descrip-
tion of the location and nature of this remodeling is lacking
(Busse, 2010). In addition, how the bronchoconstrictor is deliv-
ered (i.e., aerosol or vascular) can have an effect in human and
animal models due to the health and integrity of the epithe-
lium (Fisher et al., 1994; Turi et al., 2011) as well as the level
of mucous hypersecretion (Wagers et al., 2007), distribution of
blood flow (Holtzman et al., 1983) and the anatomical distri-
bution of airway innervation (Cabezas et al., 1971). All of the
invasive methods formeasuring lungmechanics inmice discussed
above have been validated as accurate indicators of AHR inmouse
models of asthma.
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TRANSLATIONAL UTILITY OF MURINE OUTCOME
MEASURES
TRANSLATION
Given how important human lung mechanics measurements
(lung function and AHR) are to the assessment and prediction
of the course of asthma, optimization of these measurements in
mice would be beneficial. One example of successful translation of
mouse models to human asthma is that regarding the controversy
surrounding β-agonist use in asthma. Although β-agonists are the
ultimate alleviators of acute bronchospasm, their chronic use can
be associated with a number of adverse patient outcomes includ-
ing loss of bronchoprotection, worsening of asthma control, and
asthma-related death (reviewed in Walker et al., 2011). Despite
the fact that some of these deleterious events were noticed more
than 40 years ago, little advance has been made in the compre-
hension of the physiological effects of chronic β2-AR stimulation.
Recently, Bond’s group compiled a body of evidence indicating
that β2-ARs mediate the development of allergic inflammatory
airway disease in mice (Callaerts-Vegh et al., 2004; Nguyen et al.,
2008, 2009). This group showed that β2-AR−/− mice display a
severe reduction in the asthma phenotype as do mice chroni-
cally treated with nadolol, a β2-AR inverse agonist. These studies
embraced modern techniques of lung function assessment that
mirrored those described for human asthma (Tepper et al., 2012).
Using the FOT they generated multiple-point intravenous MCh
dose-response curves and in separate groups of mice adminis-
tered an i.v. bolus of salbutamol prior to MCh dosing to assess
AHR and bronchoprotection, respectively (Callaerts-Vegh et al.,
2004). Recently, two small clinical trials from the same group
showed that chronic nadolol treatment was clinically safe and
associated with reduced sensitivity to MCh as evidenced by a
significant increase in PC20 values (Hanania et al., 2008, 2010).
Currently, the effectiveness of nadolol as a treatment for asthma
is being studied in a multi-center National Institute of Allergy and
Infectious Diseases (NIAID)-funded Clinical Trial.
ADDITIONAL CONSIDERATIONS FOR MEASURING AND REPORTING
MURINE AHR
AHR is one of the best clinical predictors for asthma control;
thus, parallel measures in mouse models of asthma promise
translational utility (Table 2). To examine both the sensitivity
and reactivity components of AHR a multi-point dose-response
curve characterized by incrementally increasing (i.e., doubling,
quadrupling or half log increments) doses of bronchoconstric-
tor should be provided. The concentration of bronchoconstrictor
that is physiologically relevant will depend on the nature of
the bronchoconstrictor, but a dose that causes a 50% increase
in baseline resistance is an acceptable midpoint for the curve.
Reporting AHR data in absolute values is preferable for a vari-
ety of reasons. Firstly, baseline resistance reported in absolute
values (either numerically or within a dose-response plot) pro-
vides a context for the bronchoconstrictor-induced changes as
well as information about tonic airway narrowing. Secondly,
reporting of absolute values affords investigators the opportu-
nity to compare and contrast the effect of genetics on the lung
mechanics responses to various disease models, as well as vari-
ations among similar protocols reported from different labora-
tories. While variability in resistance measures is expected, the
lung mechanics of mice should, like humans, fall into a range
of values since the fundamental structure and composition of
Table 2 | Comparing lung mechanics measures in humans and mice.
Human asthmatics Model of asthma
Lung function implication Human outcome
measure
Human method Murine outcome
measure
Murine method
Airflow obstruction Pre BD-FEV1 Spirometry; FEV1/FVC
compared to normals
Baseline resistance
and/or lung volume.
Invasive lung mechanics; no
bronchoreactive substance used;
compared to non-treated
controls
Airway remodeling (airflow
obstruction reversibility)
Post BD-FEV1 Spirometry; FEV1/FVC post
beta-agonist inhalation
Baseline resistance
post-BD
Invasive lung mechanics;
bronchodilator used
AHR PC20 (direct
constrictor) or PD20
(indirect constrictor)
calculated
Spirometry; FEV1 pre- and
post-increasing doses of
bronchoconstrictor
Resistance; PC100
and/or slope of dose
response curve
Invasive lung mechanics;
doubling, quadrupling or half log
increases in bronchoconstrictor
concentration; regression
analysis of dose response curve
BPE Effect of bronchodilator
on PC20; PC20
measured pre and
post-intervention
Spirometry; FEV1 at
baseline with increasing
doses of bronchoconstrictor
is measured pre- and
post-BD
Resistance; PC100
and/or slope of dose
response curve
Invasive lung mechanics; pre-
and post-BD in same mouse or
between groups comparison
The table illustrates the translational utility of lung mechanics measures made in mice to those made in asthmatics. FEV1, forced expired volume in 1 second; PC20,
provocative concentration of bronchoconstrictor that has caused a 20% decline in FEV1; BD, bronchodilator; FVC, forced vital capacity; MCh, methacholine; AHR,
airway hyperresponsiveness; BPE, bronchoprotective effect.
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the lung should not change within a strain/species. Finally read-
ers can quickly infer percent change from the absolute data.
However, if baseline values are different between groups or
not reported, then it is more difficult or impossible, respec-
tively, to make the reverse calculation. APTI is a measure that is
only obtained during a bronchoconstrictor response and there-
fore, one cannot provide a “resting” or baseline value (Levitt
and Mitzner, 1988). Stating that baseline resistance is not sta-
tistically significantly different between groups is less infor-
mative than reporting the absolute baseline values for each
group.
Many different bronchoconstrictor agents can be utilized in
both human and murine AHR tests (Brannan and Lougheed,
2012). In mice, MCh is the most commonly used bronchocon-
strictor and the route of delivery (intravenous or aerosol)
may provide additional insight into the mechanisms underly-
ing AHR (Wagers et al., 2007). For example, Wagers et al.
have shown that when MCh is administered by inhalation, as
opposed to an intravenous route, then airway mucous is more
likely to contribute to airway closure which is observed as
enhanced respiratory system resistance and elastance (Wagers
et al., 2004). Similar to human studies, the use of nebuliz-
ers to aerosolize bronchoconstrictor agents to test AHR should
be accompanied by details of the type of nebulizer and par-
ticle size generated, the duration of aerosol exposure and the
timing between aerosol exposure and resistance measurements.
Additionally, information such as the duration over which
resistance measurements are made (in relation to timing of
bronchoconstrictor administration) and the analysis method
employed (average or peak) should be provided in order to inter-
pret whether or not the relaxation phase or persistent elevation
of resistance due to airway collapse, which immediately follows
airway smooth muscle constriction, is contributing to the values
reported.
Other methodological details such as those related to mechan-
ical ventilation [positive end expiratory pressure (PEEP), breath-
ing frequency and tidal volume] can, through their impact on
lung volume and gas exchange, have a significant effect on
lung compliance, airway resistance and the health of the ani-
mal. For example, others have shown in mice that baseline and
bronchoconstrictor-induced airway resistances are inversely pro-
portional to PEEP (Sly et al., 2003; Bates and Lauzon, 2007) and
that the absence of PEEP in ventilated small mammals is likely
to result in decreased lung compliance secondary to airway clo-
sure. The peripheral structure of the lung is much more complex
than a single airway terminating at a single alveolus. Indeed,
alveoli are interconnected not only with one another (Macklem,
1971), but with branching airways embedded throughout the
parenchyma. The parenchymal tethering forces (radial traction)
on the airways is beneficial with respect to airway patency;
although there is a work of breathing trade off at high lung vol-
umes due to reduced lung compliance. PEEP maintains airway
pressure during normal passive exhalation, effectively increasing
the volume of gas in the lungs relative to that at the end of a
normal tidal breath (end-expiration). Because the mouse chest
wall is highly flexible, conscious mice (and other smaller species)
normally employ expiratory braking mechanisms or engage in
frequency-induced dynamic hyperinflation to overcome naturally
low end expiratory lung volumes and associated airway clo-
sure (Vinegar et al., 1979; Mortola, 1987). Thus, the loss of
these mechanisms under anesthesia results in a decline in end-
expiratory lung volume that can be restored to near conscious
levels by PEEP. However, murine lung volumes are sensitive to
PEEP and a 2–4 cmH2O increase in transpulmonary pressure
has been reported to produce a doubling in absolute lung vol-
ume (Lai-Fook and Houtz, 2008). Another consideration of the
effect of PEEP on end-tidal lung volume is how this relation will
be influenced by lung structural elements. For example, a given
level of PEEP will produce a lower volume in a fibrotic lung,
than for a healthy lung. Thus, a constant level of PEEP does
not necessarily equate with constant lung volume in lung dis-
ease models. In light of the above considerations, development of
standardized methodologies that assess lung function in murine
models of lung disease would enhance the ability to compare
results between separate studies and improve interpretation of
the data.
Given that one of the hallmark features of asthma is air-
flow obstruction, asthmatics experience dynamic hyperinflation
(Lougheed et al., 2006) during episodes of acute bronchospasm.
Unrelieved bronchoconstriction can promote incomplete exha-
lation, expiratory gas-trapping, and elevated end-expiratory
volume. As mentioned previously, lung volume impacts the bron-
choconstrictor response, thus interpretation of airway hyper-
responsiveness is more informed when lung volume status is
concomitantly considered. Although hyperinflation is not rou-
tinely examined during AHR measurements in mice, implemen-
tation of deep inspirations (to total lung capacity) following
the cessation of bronchoconstrictor response measurements will
relax airway smooth muscle and/or open collapsed airways to
facilitate expiration and guard against hyperinflation (Tomioka
et al., 2002). Similarly, it is recommended that deep inspirations
be administered prior to delivery of any bronchoprovocative
agent so that regions of atelectasis, which occur spontaneously
and progressively over time (Mead and Collier, 1959), can
be re-inflated. This maneuver ensures that the lung has a
consistent mechanical starting point (i.e., control of volume
history). Resistance and elastance can be measured between
doses of bronchoconstrictor to ensure that these parameters
return to control levels. These practices should be, but are
rarely, reported in the methods section of original research
articles.
The cardiovascular health of anesthetized mice is another
factor that can affect the quality of lung mechanics data.
For example, reduced cardiac output may alter the deliv-
ery of an intravenous constrictor or dilator to the airway
smooth muscle. This consideration is illustrated by the enhanced
bronchoconstrictor response to vascularly delivered muscarinic
receptor agonists (acetylcholine and MCh) in M2-muscarinic
receptor−/− mutant mice, which lack the (sinoatrial nodal)
M2-muscarinic receptor-mediated bradycardia observed in wild
type controls (Fisher et al., 2004). AHR measures can also be
impacted if treatment regimens or genetic deletions alter pul-
monary perfusion since parenchymal airways inmice are perfused
by pulmonary vessels/capillaries (Mitzner et al., 2000) rather than
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via systemic perfusion, as in humans. This unique murine
anatomy makes the delivery of intravenous bronchoconstrictors
and the circulatory clearance of any bronchoconstrictor, irrespec-
tive of its delivery method, susceptible to the hypoxic pulmonary
vasoconstrictor response (Lundblad et al., 2007).
Although not typically measured in mice, bronchoprotective
effectiveness is routinely assessed in asthmatics (Tepper et al.,
2012) (Table 2). The bronchoprotective effect is defined as the
effectiveness of a BD to protect the airways from constrictor-
induced narrowing. This measure is distinct from BD effective-
ness, or reversibility; however both are clinically relevant. The
efficacy of a β2-AR-agonist to inhibit an induced bronchocon-
striction is linked to asthma control in humans. Numerous
studies demonstrate that loss of bronchoprotection occurs with
chronic β-agonist use and that this is associated with worsen-
ing, or loss, of asthma control (Cheung et al., 1992; Bhagat
et al., 1995; Drotar et al., 1998; Lipworth et al., 1998; Jokic
et al., 2001). Consistent with the findings in human asthma,
parallel results from several murine studies demonstrated a bron-
choprotective effect of β2-AR-selective agonists (Callaerts-Vegh
et al., 2004; Tamaoki et al., 2004; Riesenfeld et al., 2010; Lin
et al., 2012). Taken together, murine models are appropriate
for studies that examine the long-term effects of β2-AR lig-
ands (short and long acting β-agonists, inverse agonists) on
asthma pathogenesis or the effect of steroids on this receptor
system.
SUMMARY AND CONCLUSION
The ATS recently assembled a task force charged with defining
asthma control and determining the clinical outcome measures
important for its assessment. The ensuing report clearly advo-
cates that lung function and AHR be the principal outcome
measures utilized in both clinical practice and clinical trials to
guide treatment and evaluation of new therapies, respectively.
Subsequently an expert panel concluded that spirometric out-
come measures are of central importance in asthma and provided
standards by which these measures should be assessed. We sug-
gest that more robust assessment of lung mechanics in mice, both
in methodology and scope, may providemechanistic information
that, coupled withmodern cell andmolecular biology techniques,
will yield better clinical translation that many seek from funda-
mental science (Holgate, 2012). Included in this report are several
specific recommendations with respect to how lung mechanics
measures in mice might be approached and reported. Perhaps the
most impactful suggestion we have made is that the utilization
and reporting of murine lung mechanics measures and protocols
become standardized.
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